
    
      Part 1 of the study includes up to 3 ascending dose cohorts, each comprised of 8 subjects (6
      receiving TD-0903 and 2 receiving placebo).

      Part 2 of the study will evaluate one dose of TD-0903 (selected based on the data from Part
      1) as compared with placebo. Part 2 is targeting 198 subjects total.
    
  